-

BostonGene Named One of Massachusetts Best Genetics and Bioinformatics Startups

 Criteria for Recognition Includes Exceptional Performance in Innovation, Growth, Management or Societal Impact

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced today that BestStartup.us had named BostonGene a top Massachusetts startup in two categories, “Genetics” and “Bioinformatics."

BestStartup.us evaluated companies on various criteria, including innovation, growth, management, or societal impact. BestStartup.us aims to highlight companies promoting innovative products and breakthrough ideas across the United States.

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to advance the standard of care, accelerate research, and improve economics. The BostonGene Tumor Portrait Test™, based on integrated genomic and transcriptomic analysis, propels precision medicine into daily clinical practice and supports physicians in actualizing personalized therapy for cancer patients. BostonGene collaborates with many of the leading cancer centers across the United States for research and clinical adoption.

“We are honored to receive this recognition from BestStartup.us,” said Erin O’Reilly, Senior Director, Marketing at BostonGene. “The acknowledgment validates our ongoing commitment to identify novel and personalized treatment options through next-generation multi-platform analytics, further advancing and optimizing outcomes for each cancer patient.”

About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

Industry:

BostonGene Corporation

Release Versions
English

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

More News From BostonGene Corporation

BostonGene Named “Overall Immunology Company of the Year” by BioTech Breakthrough for Its AI-Driven Platform That Transforms Immuno-Oncology Drug Development Through Advanced Biomarker Discovery, Real-Time Monitoring, and Precision Patient Selection

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced it has been named “Overall Immunology Company of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe. BostonGene’s AI-driven platform deli...

BostonGene to Present Seven Studies Unveiling Novel AI-Driven Breast Cancer Breakthroughs at SABCS 2025

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced seven abstracts have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS) 2025, taking place from December 9–12, 2025, in San Antonio, Texas. The research, conducted in collaboration with leading cancer centers, demonstrates the power of the BostonGene platform to uncover complex breast cancer tumor biology and drive informed, p...

BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of two abstracts for oral presentation, three abstracts for poster presentation and one abstract for online publication at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 6-9, 2025, in Orlando, Florida. BostonGene will exhibit in booth #1581. “The research we are presenting highlights the cri...
Back to Newsroom